Jayshil J. Patel

Jayshil J. Patel

Auto-generated profile, based on publicly available information

Jayshil J. Patel

Department of Cell and Developmental Biology, University College London, London, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Bone
Verified
Journal Article
Closed access
IOIsabel Orriss
Isabel Orriss
MKMichelle L. Key
Michelle L. Key
ABAndrea Brandao-Burch
Andrea Brandao-Burch
JPJessal J. Patel
Jessal J. Patel
GBGeoffrey Burnstock
Geoffrey Burnstock
TATimothy R. Arnett
Timothy R. Arnett

1 January 2012 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
ABAndrea Brandao-Burch
Andrea Brandao-Burch
MKMichelle L. Key
Michelle L. Key
JPJessal J. Patel
Jessal J. Patel
TATimothy R. Arnett
Timothy R. Arnett
IOIsabel Orriss
Isabel Orriss
Controlled ATP release has been demonstrated from many neuronal and non-neuronal cell types. Once released, extracellular ATP acts on cells in a paracrine manner via purinergic receptors. Considerable evidence now suggests that extracellular nucleotides, signaling via P2 receptors, play important roles in bone homeostasis modulating both osteoblast and osteoclast function. In this study, we demonstrate that mouse osteoclasts and their precursors constitutively release ATP into their extracellular environment. Levels were highest at day 2 (precursor cells), possibly reflecting the high number of red blood cells and accessory cells present. Mature osteoclasts constitutively released ATP in the range 0.05–0.5 pmol/ml/cell. Both osteoclasts and osteoblasts express mRNA and protein for the P2X7 receptor. We found that in osteoclasts, expression levels are fourfold higher in mature cells relative to precursors, whilst in osteoblasts expression remains relatively constant during differentiation. Selective antagonists (0.1–100 μM AZ10606120, A438079, and KN-62) were used to determine whether this release was mediated via P2X7 receptors. AZ10606120, A438079, and KN-62, at 0.1–10 μM, decreased ATP release by mature osteoclasts by up to 70, 60, and 80%, respectively. No differences in cell viability were observed. ATP release also occurs via vesicular exocytosis; inhibitors of this process (1–100 μM NEM or brefeldin A) had no effect on ATP release from osteoclasts. P2X7 receptor antagonists (0.1–10 μM) also decreased ATP release from primary rat osteoblasts by up to 80%. These data show that ATP release via the P2X7 receptor contributes to extracellular ATP levels in osteoclast and osteoblast cultures, suggesting an important additional role for this receptor in autocrine/paracrine purinergic signaling in bone.

19 June 2012 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
SSSusanne Syberg
Susanne Syberg
ABAndrea Brandao-Burch
Andrea Brandao-Burch
JPJessal J Patel
Jessal J Patel
MHMark Hajjawi
Mark Hajjawi
TATimothy R Arnett
Timothy R Arnett
IOIsabel Orriss
Isabel Orriss
Clopidogrel (Plavix), a selective P2Y12 receptor antagonist, is widely prescribed to reduce the risk of heart attack and stroke and acts via the inhibition of platelet aggregation. Accumulating evidence now suggests that extracellular nucleotides, signaling through P2 receptors, play a significant role in bone, modulating both osteoblast and osteoclast function. In this study, we investigated the effects of clopidogrel treatment on (1) bone cell formation, differentiation, and activity in vitro; and (2) trabecular and cortical bone parameters in vivo. P2Y12 receptor expression by osteoblasts and osteoclasts was confirmed using qPCR and Western blotting. Clopidogrel at 10 µM and 25 µM inhibited mineralized bone nodule formation by 50% and >85%, respectively. Clopidogrel slowed osteoblast proliferation with dose-dependent decreases in cell number (25% to 40%) evident in differentiating osteoblasts (day 7). A single dose of 10 to 25 µM clopidogrel to mature osteoblasts also reduced cell viability. At 14 days, ≥10 µM clopidogrel decreased alkaline phosphatase (ALP) activity by ≤70% and collagen formation by 40%, while increasing adipocyte formation. In osteoclasts, ≥1 µM clopidogrel inhibited formation, viability and resorptive activity. Twenty-week-old mice (n = 10–12) were ovariectomized or sham treated and dosed orally with clopidogrel (1 mg/kg) or vehicle (NaCl) daily for 4 weeks. Dual-energy X-ray absorptiometry (DXA) analysis showed clopidogrel-treated animals had decreases of 2% and 4% in whole-body and femoral bone mineral density (BMD), respectively. Detailed analysis of trabecular and cortical bone using micro–computed tomography (microCT) showed decreased trabecular bone volume in the tibia (24%) and femur (18%) of clopidogrel-treated mice. Trabecular number was reduced 20%, while trabecular separation was increased up to 15%. Trabecular thickness and cortical bone parameters were unaffected. Combined, these findings indicate that long-term exposure of bone cells to clopidogrel in vivo could negatively impact bone health. © 2012 American Society for Bone and Mineral Research.

24 February 2014 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
PDF file
JPJessal J. Patel
Jessal J. Patel
OBOliver R. Butters
Oliver R. Butters
TATimothy R. Arnett
Timothy R. Arnett

1 July 2019 in Experimental Cell Research
Verified
Journal Article
Open access
JPJessal J. Patel
Jessal J. Patel
LBLucie E. Bourne
Lucie E. Bourne
BDBethan K. Davies
Bethan K. Davies
TATimothy R. Arnett
Timothy R. Arnett
VMVicky E. MacRae
Vicky E. MacRae
IOIsabel Orriss
Isabel Orriss
Arterial medial calcification (AMC) is the deposition of calcium phosphate mineral, often as hydroxyapatite, in the medial layer of the arteries. AMC shares some similarities to skeletal mineralisation and has been associated with the transdifferentiation of vascular smooth muscle cells (VSMCs) towards an osteoblast-like phenotype. This study used primary mouse VSMCs and calvarial osteoblasts to directly compare the established and widely used in vitro models of AMC and bone formation. Significant differences were identified between osteoblasts and calcifying VSMCs. First, osteoblasts formed large mineralised bone nodules that were associated with widespread deposition of an extracellular collagenous matrix. In contrast, VSMCs formed small discrete regions of calcification that were not associated with collagen deposition and did not resemble bone. Second, calcifying VSMCs displayed a progressive reduction in cell viability over time (≤7-fold), with a 50% increase in apoptosis, whereas osteoblast and control VSMCs viability remained unchanged. Third, osteoblasts expressed high levels of alkaline phosphatase (TNAP) activity and TNAP inhibition reduced bone formation by to 90%. TNAP activity in calcifying VSMCs was ∼100-fold lower than that of bone-forming osteoblasts and cultures treated with β-glycerophosphate, a TNAP substrate, did not calcify. Furthermore, TNAP inhibition had no effect on VSMC calcification. Although, VSMC calcification was associated with increased mRNA expression of osteoblast-related genes (e.g. Runx2, osterix, osteocalcin, osteopontin), the relative expression of these genes was up to 40-fold lower in calcifying VSMCs versus bone-forming osteoblasts. In summary, calcifying VSMCs in vitro display some limited osteoblast-like characteristics but also differ in several key respects: 1) their inability to form collagen-containing bone; 2) their lack of reliance on TNAP to promote mineral deposition; and, 3) the deleterious effect of calcification on their viability.

4 October 2017 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
JPJessal J. Patel
Jessal J. Patel
DZDongxing Zhu
Dongxing Zhu
BOBritt Opdebeeck
Britt Opdebeeck
PDPatrick D'HAese
Patrick D'HAese
JMJosé L. Millán
José L. Millán
IOIsabel Orriss
Isabel Orriss